High demand, strict approval criteria, cost concerns, and frequent shortages mean insurance plans delay or restrict access to GLP-1sespecially for weight loss or non-diabetic indications
Those with decompensated cirrhosis , characterized by ascites, hepatic encephalopathy, or variceal bleeding, require alternative weight management approaches
Studies have found that higher doses can further reduce glycosylated hemoglobin and body weight, and the safety is similar to low doses
Farabegoli F, Papi A, Bartolini G, Ostan R, Orlandi M, 2010.(-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line
GIP stands for glucose-dependent insulinotropic polypeptide, another hormone involved in appetite regulation and metabolism